Skip to content
The Orphan Drug Act (ODA) celebrates its birthday on January 3. The year 2024 marks 41 years of revolutionizing drug development for rare diseases […]
Orphan Drug Act: 40+ years of fighting rare diseases Read More »
The Inflation Reduction Act (IRA) exempts orphan drugs for rare diseases from price controls—but only if the drugs are approved for a single indication.
American biotech industry, voters support ORPHAN Cures Act Read More »
We are one step closer to pharmacy benefit manager (PBM) reform. The U.S. House approved the Lower Costs, More Transparency Act (H.R. 5378) on
House passes Lower Costs, More Transparency Act Read More »
On World AIDS Day, biotech – and the world – are reminded that we can help end HIV/AIDS through medical advances and improvements in
World AIDS Day: Biotech and equity are allies in eradicating this disease Read More »
November is National Alzheimer’s Disease Awareness Month—a time to recognize and support patients and their families and put a renewed focus on the need
Alzheimer’s Disease Awareness Month: 2023 brings progress, focus on access Read More »
The Federal Trade Commission (FTC) challenge of more than 100 patent listings registered with the Food and Drug Administration, mostly for devices used to
The Biotechnology Innovation Organization (BIO) and patient advocacy organizations have seen some recent progress in their efforts to have Congress pass pharmacy benefit manager
House and Senate advance PBM legislation, advocacy groups urge passage Read More »
Pharmacy benefit managers, or PBMs, have been in the political hot seat for a couple of years now—and for good reason. “Every day PBMs
As PBM reform maintains steam, biotech companies and patients are urged to take action Read More »
Blood clots are commonly missed. According to the National Blood Clot Alliance (NBCA), “fewer than 1 in 4 people have any recognition of blood
A new class of medicines provides hope for patients at risk of dangerous blood clots Read More »
Federal Trade Commission (FTC) proposals for new rules to permit more aggressive opposition to mergers would interfere with the economic ecosystem that is essential
FTC plans for aggressive merger enforcement threaten biotech innovation, BIO says Read More »
